CD38 and acute myeloid leukemia: However given that LSCs contained within CD34+CD38-CD123+ population in AML and difficulty to eradicate these malignant cells in this subgroup supports the hypothesis that in order to maintain complete remission after induction chemotherapy and to improve survival in AML patients, traditional chemotherapy targeting blasts should be combined with agents targeting LSCs.